Is zomedica stock a good buy?
At first glance, Michigan-based veterinary testing and pharmaceutical product specialist Zomedica (NYSEAMERICAN: ZOM) might sound like a great company to invest in. After all, ZOM stock is really cheap, and pet healthcare certainly sounds like a high-growth niche market.
What does zomedica’s Q3 results mean for investors?
After reading Zomedica’s third-quarter financial results, investors will need to be very motivated to stand by the company. The press release stated that Zomedica’s total Q3 revenue was, believe it or not, just $22,514.
Is zomedica’s CEO on a mission to rescue pets?
Zomedica’s recently installed CEO seems to be on a mission to rescue not pets, but a financially strapped business. As we’ll see, Zomedica’s recent press releases are noble attempts to drum up enthusiasm among skeptical stock traders.
How much did zomedica (Zom) lose in 2021?
Furthermore, Zomedica reported that, during the nine months that ended on Sept. 30, 2021, the company only generated $52,331 in revenue and incurred a staggering net earnings loss of $15.1 million.
Does Vanguard own Zomedica?
Vanguard Group Inc reports 2.77% decrease in ownership of ZOM / Zomedica Pharmaceuticals Corp. 2022-05-13 - Vanguard Group Inc has filed a 13F-HR form disclosing ownership of 40,480,501 shares of Zomedica Pharmaceuticals Corp. (US:ZOM) with total holdings valued at $13,642,000 USD as of 2022-03-31.
Who bought Zom?
Novartis has bought the rights to Xoma's gevokizumab. The Swiss Big Pharma is paying $31 million (€26 million) upfront for the anti-IL-1 beta allosteric monoclonal antibody, a price that reflects the battering its prospects took as a late-phase clinical development program unraveled.
How many shares of Zomedica are there?
Share StatisticsAvg Vol (3 month) 318.82MShares Outstanding 5979.9MImplied Shares Outstanding 6N/AFloat 8966.83M% Held by Insiders 12.56%7 more rows
Why did Zomedica stock drop?
The reason behind the decline goes back into the previous week, when Zomedica announced its third-quarter results after the market close on Nov. 12. The veterinary health company reported revenue in the third quarter of only $22,514. It posted a net loss of $6.3 million, or $0.091 per share.
Is Zomedica a good investment?
In the final analysis, ZOM stock is highly risky and best suited for speculative traders. Yet it's possible that retail traders will bid the stock up in 2022. And if they abandon Zomedica, it would be a dog-gone shame.
Is Zomedica expected to rise?
Zomedica Stock Price Forecast 2022-2023 The forecasted Zomedica price at the end of 2022 is $0.39 - and the year to year change +27%. The rise from today to year-end: +50%. In the middle of 2022, we expect to see $0.30 per 1 Zomedica.
Is Zomedica being shorted?
Zomedica saw a increase in short interest in the month of May. As of May 31st, there was short interest totaling 116,080,000 shares, an increase of 3.1% from the previous total of 112,640,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment.
Is Zomedica a pump and dump?
Zomedica Pharmaceuticals (NYSEMKT:ZOM) stock is the latest pump-and-dump looking to take investors for a ride.
Will ZOM be delisted?
The NYSE American LLC told Zomedica that it's no longer in danger of being delisted. The exchange can remove a stock if it closes at less than $1 for more than 30 consecutive days. That's no longer the case for Zomedica.
What is the target price for ZOM stock?
Stock Price TargetsHigh$1.20Median$1.20Low$1.20Average$1.20Current Price$0.26